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Abstract
Background: Acute pharyngitis accounts for an estimated 15 million patient visits in the United States. However,
there is no proven effective and safe treatment. Although Chinese herbal medicine is widely used in the treatment
of acute pharyngitis, there is a lack of evidence-based data. Despite several clinical trials conducted in this setting,
no randomized placebo-controlled trial has been performed to date. This trial aims to investigate the efficacy and
safety of Qi-Wei-Qing-Yan aerosol (QWQYA), a Chinese herbal prescription, compared with a placebo aerosol in the
treatment of acute pharyngitis with lung-stomach excess-heat syndrome.
Methods/design: This is a prospective, multicenter, randomized, double-blinded, parallel-group, placebo-controlled
trial. A total of 420 adult patients, of either sex, with acute pharyngitis will be enrolled from seven study sites across
China. All patients will be randomly allocated to one of three parallel treatment groups: (1) QWQYA with the
current propellant, (2) QWQYA with a previous propellant, and (3) the placebo aerosol with the current propellant. The
study medication will be administered into the pharyngeal region in three sprays thrice daily for 5 consecutive days.
The primary outcome measures are time to complete resolution of sore throat and relief rate of sore throat. Secondary
outcome measures include resolution rate of sore throat, time to relief of sore throat, intensity of sore throat, and
change of traditional Chinese medicine syndrome score and clinical signs score from baseline to post-treatment,
as well as the occurrence of any adverse events.
Discussion: This will be the first clinical trial to investigate the efficacy and safety of QWQYA in the treatment of acute
pharyngitis in an adult population in a multicenter, randomized, double-blinded, parallel-group, placebo-controlled
manner. Not only might it establish the basis for the efficacy and safety of QWQYA in treating acute pharyngitis, but it
might also provide evidence to support the use of Chinese herbal medicine in treating acute pharyngitis and thus
support an alternative treatment option for management of acute pharyngitis.
Trial registration: Chinese Clinical Trial Registry ChiCTR-IPR-15005991.
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Background
Acute pharyngitis is characterized by an inflammation of
mucous membranes of the pharynx and the surrounding
lymphoid tissue and accounts for an estimated 15
million patient visits in 2006 in the United States [1]. It
is commonly caused by various viral or bacterial infec-
tions. Viruses are the most common cause, accounting
for up to 40 % to 60 % of cases [2]. The most common
type of bacterial infection is group A beta-hemolytic
streptococcal (GABHS) infection, which is responsible
for around one-third of pediatric pharyngitis but only
5 % to 10 % of adult pharyngitis [3, 4]. An acute onset of
sore throat is the predominant symptom, accounting for
more than 10 % of all primary care visits [1].
Antibiotics are indicated to prevent suppurative com-
plications and rheumatic fever, and decrease infectivity,
but may only provide limited benefit in the resolution of
symptoms, shortening sore throat duration by less than
1 day [5]. Moreover, excessive or inappropriate use of
antibiotics may be associated with the potential side ef-
fects, increased antibacterial drug resistance, and high
medical costs [6, 7]. Given that the majority of cases are
caused by viral pathogens, the current treatment strategy
in adults focuses on the relief of symptoms, particularly
sore throat. Corticosteroids may reduce the severity and
duration of pain, but corticosteroids alone should not
be administered as routine treatment, owing to poten-
tial side effects [8–10]. Nonsteroidal anti-inflammatory
drugs can reduce sore throat pain in 24 hours but are
associated with gastrointestinal, renal, or hepatic
adverse effects [11]. Although gargles or lozenges with
local anaesthetic also provide sore throat pain relief,
the effect is short-lived or temporary [3, 12].
Owing to a lack of proven effective and safe therapies
in Western medicine, an increasing number of patients
turn to complementary and alternative medicine [13–15],
including traditional Chinese medicine, for relief of symp-
toms of acute pharyngitis. In traditional Chinese medicinal
theory, acute pharyngitis falls into the disease category of
pharyngitis (houbi in Chinese Pinyin), and is mainly
caused by external causes, including wind and heat. Based
on traditional Chinese medicinal clinical practice, wind-
heat syndrome and lung-stomach excess-heat syndrome
are the most common syndromes. Of these, lung-stomach
excess-heat syndrome is more common in patients, with
underlying heat in the lungs and stomach, and is primarily
characterized by sore throat, cough, dryness of throat,
thirst, and fever. The general traditional Chinese medi-
cinal therapeutic principle is to clear away heat and toxins,
and to relieve the sore throat.
Although traditional Chinese medicine has been
widely used in China for the treatment of acute pha-
ryngitis for thousands of years, Chinese herbal medi-
cine is not recommended for use as an effective
therapy, owing to the lack of high-quality clinical trials in
this area [16]. Qi-Wei-Qing-Yan aerosol (QWQYA) is a
registered herbal prescription in China and manufactured
by Shandong Bencao Pharmaceutical Co., Ltd (Shandong,
China). Table 1 lists the detailed formula. Despite the use
of QWQYA in acute pharyngitis for several years, its
efficacy has never been investigated through a placebo-
controlled trial. Moreover, dichlorodifluoromethane
(CFC-12), the previous propellant of QWQYA, has
gradually been banned by the Ministry of Environmen-
tal Protection of the People’s Republic of China, owing
to its ozone-depleting properties [17]. Alternatively,
1,1,1,2-tetrafluoroethane (HFC-134a) is used as the
current aerosol propellant, owing to its negligible ozone
depletion potential [18]. Accordingly, the safety of
QWQYA with the current aerosol propellant remains
unknown.
The objective of this trial is to evaluate the efficacy
and safety of two QWQYAs (active medication with
the current or previous propellant) in comparison
with a placebo aerosol (placebo with the current propel-
lant) in patients with acute pharyngitis (lung-stomach
excess-heat syndrome). In this study, the investigators
hypothesize that (1) time to complete resolution of sore
throat will be shorter in the groups using QWQYA with
the current or previous propellant; (2) the proportion of
patients who achieve sore throat pain relief will be higher
in the groups using QWQYAs; and (3) QWQYA with the
current propellant will be safe.
Methods/design
This is a prospective, multicenter, randomized, double-
blinded, parallel-group, placebo-controlled trial of two
QWQYAs (active medication with the current or previ-
ous propellant) versus placebo aerosol (placebo with
the current propellant) for acute pharyngitis. The study
has been authorized by the China State Food and Drug
Administration (Approval No. 2014 L00188). In addition,
the study was registered with the Chinese Clinical Trial
Registry (ChiCTR-IPR-15005991). The trial protocol is
conducted in accordance with the Declaration of Helsinki,
the code of Good Clinical Practice, and the guidelines of
Table 1 Formula of Qi-Wei-Qing-Yan aerosol
Pinyin name Botanical or zoological authority Family name
Shandougen Euchresta japonica Hook. f. ex Regel Leguminosae
Shegan Belamcanda chinensis (L.) Redouté Iridaceae
Xuanshen Scrophularia ningpoensis Hemsl. Scrophulariaceae
Maidong Ophiopogon japonicus (L. f.) Ker-Gawl. Liliaceae
Chansu Bufo bufo gargarizans Cantor Bufonidae
Rengong
Shexiang
Moschus (Artificial) Not applicable
Bingpian Dryobalanops aromatica Gaertn.f. Dipterocarpaceae
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the International Conference on Harmonisation. Recruit-
ment is scheduled to occur from early April 2015 until
October 2015. Figure 1 shows the flow chart of the trial.
Patient population and setting
The diagnosis is made by medically qualified physician
based on the presence of acute onset symptoms and
signs suggestive of acute pharyngitis [19]. All patients
will be screened for Centor criteria (history of fever
(>38 °C), tonsillar exudates, tender anterior cervical
adenopathy, and lack of cough) to focus on viral acute
pharyngitis. Adults with none or only one of these find-
ings will be included. Traditional Chinese medicinal
diagnosis of lung-stomach excess-heat syndrome is
based on the Guidelines for Clinical Research of New
Chinese Medicine [20]; detailed criteria are presented in
Table 2.
A written, signed, and dated informed consent
form should be obtained from each patient before
any study specific procedures are performed. The
participant information sheet and informed consent
form will be presented to patients by the responsible
clinician, who will explain the exact nature of the
study, the implications and constraints of the proto-
col, the known side effects, and any benefits or risks
involved in participation, and the importance of
completing the study. It is clearly stated that the
participant is free to withdraw from the study at any
time for any reason without prejudice to future care,
and with no obligation to give the reason for
withdrawal.
A total of 420 patients of either sex, aged 18–65
years, will be enrolled from seven study sites across
China: (1) West China Hospital of Sichuan University,
(2) Xiyuan Hospital of China Academy of Chinese
Medical Sciences, (3) the first Affiliated Hospital of
Guiyang College of Traditional Chinese Medicine, (4)
Ruikang Hospital Affiliated to Guangxi University of
Chinese Medicine, (5) the Affiliated Hospital of
Shanghai University of Traditional Chinese Medicine,
(6) the Affiliated Hospital to Liaoning University of
Traditional Chinese Medicine, and (7) the Affiliated
Hospital of Chengdu University of Traditional Chin-
ese Medicine. A research assistant in each center will
recruit patients either from outpatient departments,
or through advertisements in community hospitals or
pharmacies. Each participating center will recruit 60
patients.
Inclusion criteria
1. Clinical diagnosis of acute pharyngitis;
2. Lung-stomach excess-heat syndrome in traditional
Chinese medicine;
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Fig. 1 Study flow chart. QWQYA Qi-Wei-Qing-Yan aerosol
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3. Within 48 hours of onset;
4. Centor criteria ≤1;
5. Baseline sore throat score by visual analog scale of
5 or more, and by traditional Chinese medicine
score of 6 or more;
6. Aged 18 to 65 years;
7. Patient must voluntarily give written, informed
consent and report adverse events and concomitant
medication for duration of study.
Exclusion criteria
1. Patients with temperature greater than 38.5 °C;
2. Use of any medication taken for relief of sore throat
prior to study initiation;
3. Current use of analgesic or anti-inflammatory
regimen, such as analgesics, nonsteroidal
anti-inflammatory drugs, or steroids;
4. Chronic pharyngitis;
5. Patients with any suspected or known heart disease;
6. Sore throat caused by local irritation of mucous
membranes due to gastroesophageal reflux or
ingestion of caustic substances;
7. Patient with severe primary disease of pulmonary,
hepatic, renal, or hematological system, or other
serious diseases affecting survival, such as cancer
or AIDS;
8. Abnormal results to myocardial markers test,
electrocardiogram abnormality, alanine transaminase
or aspartate aminotransferase > 1.5 times of normal
upper limit, abnormality of serum creatine, white
blood cell count < 3 × 109/l or >10 × 109/l, and
neutrophil granulocyte >80 %;
9. Pregnancy or potential pregnancy or lactation;
10. Allergic constitution or known allergy to any
component in QWQYA;
11. Patients taking similar medicines in the previous
month or having participated or participating in
other trials in previous 3 months;
12. Mentally or legally disabled patients.
Withdrawal criteria
Once randomly allocated to a group, a patient will be
regarded as included in the study. However, patients
may voluntarily withdraw from the study at any time for
lack of efficacy, worsening condition, or any other rea-
son. Researchers can withdraw patients from the trial
owing to patients’ lost to follow-up, development of
allergic reaction, serious adverse events, condition
apparently worsening, use of forbidden medications or
treatments, unblinding, or actual usage of trial medi-
cation of <80 % or >120 % of the required dosage.
Withdrawn patients will not be replaced. Any participant
will be perceived as having completed the study if all post-
treatment assessments have been performed.
Termination criteria
The entire study will be terminated prematurely or
suspended by the investigators in the case of serious
adverse events, poor efficacy observed during the study,
or significant deviation from the protocol, by the
National Pharmaceutical Supervisory and Administrative
Department for any reason, or by the sponsor due to
management or funding problems.
Randomization and blinding
Stratified blocked randomization will be applied in the
study. Randomization sequence is generated in blocks of
seven in a 1:1:1 ratio by an independent statistician not
involved with the participants’ enrollment or study ana-
lysis, using Statistical Analysis System SAS (SAS 9.3).
The random treatment assignment for each patient will
be concealed and stored in advance in two opaque,
sealed, sequentially numbered envelopes. Each set of en-
velopes corresponds to a unique allocation code contain-
ing the specified treatment group. The sealed envelopes
are kept in a fireproof place, and will only be opened in
case of a medical emergency. Participants, investigators,
coordinators together with statisticians are all blinded to
group assignments throughout the study.
Investigational medicinal product
Both QWQYAs contain 6.2 g/7 ml of the active solution
with the excipients of ethanol, propylene glycol, and
span-80 (one with the current propellant and the other
with the previous propellant). Placebo aerosol with the
current propellant contains 0.31 g/7 ml of placebo solu-
tion with the same excipients for appropriate blinding.
Each spray equals 32.6 mg/0.037 ml of active solution
and 1.6 mg/0.037 ml of placebo solution.
Both active and placebo aerosols are manufactured by
Shandong Bencao Pharmaceutical Co., Ltd., in accord-
ance with the principles of Good Manufacturing Prac-
tice. Medication supplies are coded, packed, and labelled
in a blinding manner according to the randomization
Table 2 Traditional Chinese medicine syndrome diagnostic
criteria for lung-stomach excess-heat syndrome
Category Symptoms or signs
Main symptom Sore throat
Minor symptoms Cough, dryness of throat, thirst, fever,
dry stool, deep-colored urine
Tongue appearance Light red appearance
Tongue coating Thin yellow coating
Pulse Rapid and powerful pulse
The syndrome can be diagnosed by the presence of the main symptom and ≥3
minor symptoms.
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list. Each investigational medicinal product package
contains an aerosol. Both active and placebo aerosols are
issued in bottles identical in shape, size, and color. A
clearly visible label on each package states ‘FOR TRIAL
USE ONLY’ and other information, including function
and indication, name, dose, dosing schedule, storage
condition, expiry date, and the manufacturer’s name. An
independent drug administrator in each center is re-
sponsible for receipt, handling, storage, dispensing, and
retrieval of all investigational medicinal products. The
standard operating procedures, and the manner in which
the records are kept, must be documented. An overview
of consent, screening, enrollment, intervention, timing
of measurements, and data collection is shown in Fig. 2.
Interventions
All participants are randomly allocated to one of three
parallel treatment groups: (1) QWQYA with the current
propellant, three sprays into the pharyngeal region thrice
daily; (2) QWQYA with the previous propellant, three
sprays into the pharyngeal region thrice daily; and (3)
the placebo aerosol, three sprays into the pharyngeal
region thrice daily. The scheduled treatment duration
will be 5 consecutive days.
Concomitant treatments and forbidden medication
Patients can take any Western medication or other
Chinese herbal medicine that may relieve sore throat or
other symptoms of acute pharyngitis, or use antibiotics
and anti-viral agents during the study, but then they will
be withdrawn from the study. Medications used to con-
trol underlying conditions, such as hypertension or dia-
betic mellitus, are allowed. Any concomitant treatment
or medication administered must be recorded carefully
in case report forms, including the name, dose, dosing
schedule, mode of administration, and treatment period.
Drug adherence and compliance
Drug adherence is expected to be good, owing to the short
study duration of 5 days and three visits after recruitment.
Measures taken to maximize adherence include careful
screening, fully informing patients of the potential benefits
and risks, and attentive follow-up. Compliance will be
checked by patients’ documented daily diaries, reporting
how many sprays and times they apply the study medica-
tion, and by weighing each dispensed aerosol on the date
on which the study medication is issued, and again on the
date on which it is returned by the patient.
Outcome measures
Primary outcome measures
1. Time to complete resolution of sore throat, i.e., length
of time from the start of treatment until complete
resolution. Sore throat will be assessed using an
11-point (0 to 10) numeric visual analog scale, with 0
indicating ‘no pain’ and 10 indicating ‘worst
possible pain’. This score will be evaluated thrice
daily, immediately before spraying. Complete
resolution of sore throat is defined as a reduction
of the score to 1 or less, lasting for more than
24 hours [21].
2. Relief rate of sore throat: this is defined as a
reduction by 50 % in the baseline visual analog
scale score recorded prior to treatment (day 0),
lasting for more than 24 hours. The relief rate of
sore throat is the proportion of patients who
achieve relief of sore throat.
Secondary outcome measures
1. Resolution rate of sore throat: proportion of patients
who achieve complete resolution of sore throat.
2. Time to relief of sore throat: length of time from the
start of treatment until pain relief.
3. Change of intensity of sore throat: assessed by visual
analog scale from baseline to post-treatment.
4. Change of traditional Chinese medicine
syndrome score from baseline to post-treatment:
each traditional Chinese medicine symptom is
graded (Fig. 3), and the traditional Chinese
medicine syndrome score is the accumulated
score of the main symptom score and all minor
symptom scores.
5. Change of clinical signs score.
Three primary clinical signs in acute pharyngitis will
be observed and recorded before and after treatment.
The detailed scoring criteria are shown in Fig. 3.
Safety outcome measures
Safety outcome measures include monitoring of ad-
verse events, as well as clinical and laboratory find-
ings. In addition to routine tests of blood, urine, and
stool, hepatic and renal functions, and myocardial
markers, electrocardiography will also be performed at
baseline and again after treatment, to assess safety for
each group. Patients will be required to record any un-
expected symptoms or signs during the treatment
period.
Data management, monitoring, and auditing
A paper case report form will be used to collect data. To
ensure maximum follow-up evaluation, the following
measures will be taken:
1. Train investigators and study staff in the importance
of keeping participants in the trial until the end.
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2. Ensure that participants completely understand the
research objectives and importance of completing
the study.
3. Keep contact information for participants including
phone numbers, email addresses, and mailing
addresses.
4. Remind participants of their appointments.
5. Make follow-up appointments at each participant’s
convenience.
6. Provide a remuneration of Chinese ¥200 after
completing the study.
7. Provide continued access to effective treatments
after the trial for patients whose symptoms are not
yet cured.
Fig. 2 Schedule of study procedures. Participants will receive the study medication for 5 days after enrollment and allocation. The time-points of
assessments are shown in the schedule. QWQYA, Qi-Wei-Qing-Yan Aerosol; TCM, traditional Chinese medicine; VAS, visual analog scale
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8. Make efforts to obtain the participant’s consent for
the collection of data outcomes when medication
discontinuation occurs.
After completion of data collection, double data
entry will be performed to transcribe the data into
the computer database as soon as possible after re-
cruitment and follow-up evaluation so that the patient
and data collector are still available if responses are
found to be missing or out of range. All information
on the patients and outcome variables will be stored,
updated, and monitored using EpiData3.1, which will
also be used to format the data for statistical analysis.
Regular backups and off-site storage will be con-
ducted, to prevent loss of the database. The principal
investigator, data managers, sponsor, and statisticians
will confirm and lock the database prior to data pro-
cessing. Only data managers and statisticians will have
access to the final data. Original case report forms
and any other records will be kept on file at each
study site for 5 years.
Interim analyses will not be performed, as the inves-
tigational product is a registered and clinically used
aerosol and the study is scheduled to last for approxi-
mately 6 months. An independent data monitoring
committee will be set up to monitor patient safety and
treatment efficacy data. Moreover, a monthly progress
report on enrollment, recruitment, study participa-
tions, safety, and completion will be issued to the prin-
cipal investigator. The regulatory authority at each
study site and auditors independent of the investiga-
tors and sponsor will conduct a monthly audit, includ-
ing, but not limited to, trial procedure and compliance
with the protocol, standard operating procedures, code
of Good Clinical Practice, and the applicable regulatory
requirements. Any observation or finding should be
documented.
Adverse event reporting
An adverse event will be defined as any unfavorable and
unintended sign (including abnormal laboratory find-
ings), symptom, or disease temporally associated with
Fig. 3 Symptoms and signs score. TCM, traditional Chinese medicine
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the use of the study medication. All adverse events
will be recorded in detail, including event, date of oc-
currence, grade, whether expected or unexpected, date
resolved, and treatment patients receive specifically
related to the event, and will be categorized as clearly
not, doubtfully, may be, likely, or clearly related to
the study medication. A serious adverse event will be
defined as any untoward medical occurrence that, at
any dose, results in death, is life-threatening, requires
inpatient hospitalization or prolongation of existing
hospitalization, results in persistent or significant dis-
ability or incapacity, is a congenital anomaly or birth
defect, or other important medical event. Other
events that are not likely to result in death, are not
life-threatening, or do not require hospitalization,
might be considered as serious adverse event if the
event might jeopardize the patient and might require
medical or surgical intervention to prevent one of the
outcomes listed above.
Medically qualified investigators will record, assess,
and report adverse events. Non-serious adverse
events will be recorded in case report forms, and
listed in a monthly progress report to the principal
investigator and sponsor. Serious adverse events
must be reported to the institutional review board,
principal investigator, sponsor, and the Drug Regis-
tration Division of China’s State Food and Drug Ad-
ministration and Research within 24 hours. The
blinding procedures will be broken in case of a med-
ical emergency.
Sample size calculation
The sample size was calculated on the basis of the two
primary outcomes, using ‘Non-inferiority tests for two
proportions [differences]’ in PASS 11.0. Based on a pre-
vious study [22], the mean time to complete resolution
of sore throat in both active treatments was similar, both
with a standard deviation of 2.2 days. A difference of
1 day or more between groups was regarded a clinically
important effect. Setting a one-sided α of 0.05 and β of
0.1, the sample size was estimated to be 84 cases for
each group. Based on consultation with clinical experts
and a preliminary unpublished study provided by the
sponsor, the relief rate of sore throat in QWQYA
with previous propellant was estimated at 91 %, with
a difference of 10 % or more considered clinically sig-
nificant. The sample size was estimated at 118 partici-
pants for each group, assuming a one-sided α of 0.05
and β of 0.15. Both the sample sizes were calculated
according to the formula:
n = 2 Z1−α=2þZβð Þσ
δ−Δ
 2
Therefore, the final sample size for each group was
118 participants. Taking approximate dropout rates of
20 % into account, the number of participants to be
recruited was estimated at 140 per group. Therefore, a
total of 420 patients will be recruited in this trial.
Statistical analysis
An independent statistician will perform statistical
analysis using SAS 9.3. The full analysis set popula-
tion includes all randomized participants as allo-
cated. Only missing data regarding the primary
outcomes will be adjusted using the last observation
carried forward method. The per-protocol popula-
tion includes only patients who fulfil the protocol.
Analysis of efficacy will be performed based on the
full analysis set and per-protocol population. Safety
analyses will be performed in those populations,
which include all randomized participants who receive
at least one spray of medication and who have at least one
visit for safety, whether or not they are withdrawn
prematurely.
A fully specified statistical analysis plan will be
written before unmasking. Quantitative variables will
be described as mean ± standard deviation or median,
and qualitative variables as frequency and percentage.
Baseline analyses will be performed using analysis of
variance (ANOVA) or rank-sum test for quantitative
data and chi-squared or Fisher’s exact test for quali-
tative data. A non-inferiority test will be used to
compare the two active QWQYA groups, and a su-
periority test to compare the current-propellant
QWQYA group and the placebo group. A one-sided
confidence interval method will be used in efficacy
analyses. Statistical significance will be considered for
P ≤ 0.05.
Ethical considerations and dissemination
The study protocol has been reviewed and approved
by the Biomedical Ethics Committee of West China
Hospital of Sichuan University (Chengdu, China). Any
modifications, including the principal investigator,
study protocol, and informed consent forms must be
re-submitted, reviewed, and approved by the Biomedical
Ethics Committee. Trained research investigators will
explain the study procedures using information
sheets, which will be provided to all potential partici-
pants prior to participation. All participants must
voluntarily give their written, informed consent prior
to any study procedures. Participants with impaired
decision-making capacity who might have difficulty
weighing the risks and benefits of the study will be
excluded from this study. The principal investigator,
sponsor, ethical committees, and drug regulation
agencies have access to individual patient’s data, and
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no ancillary studies will use these participants’ data.
Moreover, each patient will be identified with a
unique identity without any other personal identifier
for purposes of maintaining confidentiality. This study
protocol has been prepared according to the SPIRIT
checklist [23].
Additionally, chest X-rays will be obtained in selecting
eligible participants, to exclude patients with lower re-
spiratory tract infection, and a urine pregnancy test
(strip) will be used to detect early suspected or unknown
pregnancy in women with child-bearing potential.
A preliminary study (an unpublished observation
by Professor Jia Miao) suggests that QWQYA might
be associated with a risk of mild reduction of heart
rate within normal range. However, another two tri-
als [24, 25] did not find any such association. In this
study, myocardial markers will be tested and electro-
cardiography will be performed in potential partici-
pants, and a detailed history will be taken, to exclude
those with an underlying heart disease. In addition,
the test of myocardial markers and electrocardiog-
raphy will be performed again after treatment to
monitor participants for potential adverse effects.
The results of this study will be presented at national
or international conferences and submitted to peer-
reviewed journals.
Discussion
A Cochrane review [16] of 12 randomized controlled
trials that assessed the efficacy and safety of Chinese
herbal medicine for sore throat found that trials in
this area were methodologically of poor quality, with
controversial and questionable evidence of efficacy.
Moreover, the randomized controlled trials included
in this review and trials conducted thereafter [26–28]
all used a ‘positive effect drug’ as a control, compar-
ing the Chinese herbal medicine under investigation
with another Chinese herbal medicine or a Western
medicine. However, the efficacy of these ‘positive ef-
fect drugs’ has not yet been well established. To the
best of our knowledge, this will be the first multicen-
ter, double-blind, randomized, placebo-controlled trial
of Chinese herbal medicine designed to treat acute
pharyngitis in an adult population. Not only might it
establish the basis for the efficacy and safety of
QWQYA in the treatment of acute pharyngitis, but it
might also provide evidence regarding Chinese herbal
medicine for treating acute pharyngitis and an alter-
native treatment option for the management of acute
pharyngitis.
This trial is placebo-controlled and focuses on viral
pharyngitis in adults. Although it is not always easy
to distinguish viral from bacterial causes, laboratory
confirmation of bacteria, including a rapid antigen
detection test and throat culture is not indicated and
recommended in adults with a lower likelihood of
GABHS infection [29]. In this trial, Centor criteria (a
history of fever, tonsillar exudates, tender anterior
cervical adenopathy, and lack of cough) will be
applied to exclude patients with potential GABHS
pharyngitis, with the absence of three or four of the
criteria indicating a negative predictive value of more
than 80 % [30, 31].
It is well-known that the gold standard for assessing
the efficacy of specific intervention is a randomized
placebo-controlled trial. Ideally, a placebo should be
an inactive substance that is pharmacodynamically
inert. However, it is significantly difficult to develop
appropriate placebos, in terms of smell, taste, and
color, in clinical trials of herbal medicine especially
those of compound formula in a liquid form. To our
knowledge, no validated placebo of Chinese herbal
medicine has been developed in the setting of acute
pharyngitis. Moreover, several clinical trials outside
the setting of acute pharyngitis have applied 10–20
times dilutions of active herbs as placebos in China
and Japan [32, 33]. In this trial, one-twentieth of the
total dose of active solution is used as the placebo,
since it is assumed to be unlikely that a tiny amount
of 14.4 mg per day could be an effective treatment.
Both the active aerosols and the placebo aerosol are
issued in bottles identical in size, shape, and color, to
ensure appropriate blinding. In addition, participants
are required not to communicate with each other, to
minimize the possibility of revealing differences be-
tween the placebo and active medication.
Trial status
This trial is preparing for patient recruitment at the time
of manuscript submission.
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